Document is current
Any future updates will be listed below
-
Authors
Breen, William G. http://orcid.org/0000-0001-8039-2398
Young, Jason R. http://orcid.org/0000-0001-5351-8266
Hathcock, Matthew A.
Kowalchuk, Roman O.
Thorpe, Matthew P.
Bansal, Radhika http://orcid.org/0000-0003-0964-098X
Khurana, Arushi
Bennani, N. Nora http://orcid.org/0000-0001-8358-5953
Paludo, Jonas http://orcid.org/0000-0002-7350-5531
Bisneto, Jose Villasboas http://orcid.org/0000-0002-2907-0809
Wang, Yucai http://orcid.org/0000-0002-1576-8341
Ansell, Stephen M. http://orcid.org/0000-0003-1244-6758
Peterson, Jennifer L.
Johnston, Patrick B.
Lester, Scott C.
- License Information
-
More Information
Article History
Received: 4 April 2023
Revised: 11 July 2023
Accepted: 1 August 2023
First Online: 18 August 2023
Competing interests
: Jonas Paludo received research funding from Karyopharm. Yucai Wang received funding from Incyte, LOXO Oncology, Novartis, Genetech, and Morphosys; also had Incyte, LOXO Oncology, Eli Lilly, TG Therapeutics membership on the advisory committee. William Breen received from GE Healthcare regarding Estradiol PET scans that were not related to the project but paid to the institution. Yi Lin received research funding from Kite, Janssen, Celgene, Bluebird Bio, Merck, and Takeda; also received consulting fees from Janssen, Novartis, Celgene, Bluebird Bio, Juno, Legend, Sorrento, Gamida Cell, and Vineti. Also, LOXO Oncolgy, Incyte, Eli Lilly, and TG Therapeutics were taking part on an advisory committee. Stephen Ansell received from Bristol Myers Squibb, ADC Therapeutics, Seattle Genetics, Regeneron, Affimed, AITherapeutics, Pfizer, Trillium, and Takeda.
